Sonoma Pharmaceuticals Reports FY and Q4 2024 Financial Results

DENVER, Colo., Jun 18, 2024 (247marketnews.com)- Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA) reported fiscal year 2024 and the fourth quarter, ended March 31, 2024, financial results.

Highlights include 14% revenue increase for the fourth quarter 2024, compared to the fourth quarter of 2023, 3% gross profit margin improvement for the fourth quarter 2024, compared to the fourth quarter of 2023, and net loss for fourth quarter 2024 improved 18%, compared to the fourth quarter of 2023

“We are pleased to report continued product-related growth and reduced cash burn in both our fourth quarter and fiscal year 2024 results. Fueled by significant worldwide demand for our technology, we’ve expanded our revenue channels and developed new products over the past year,” stated Sonoma’s CEO, Amy Trombly. “We remain focused on control of expenses and identifying new growth opportunities as we drive the business toward profitability.”

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://www.247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
[email protected]

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.